<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419624</url>
  </required_header>
  <id_info>
    <org_study_id>UKE-DapEx-001</org_study_id>
    <nct_id>NCT03419624</nct_id>
  </id_info>
  <brief_title>The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients</brief_title>
  <official_title>A 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 28-week, multi-center, randomized, double-blind, placebo-controlled trial to study
      a potential synergistic effect of Dapagliflozin plus Exenatide once-weekly in combination
      with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant
      patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c≥8.0% and
      ≤ 11.0%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this proof-of-concept study the potential of treatment with Dapagliflozin plus Exenatide
      added to high-dose intensive insulin therapy compared to Placebo added to high-dose intensive
      insulin with active insulin up-titration for change in HbA1c from baseline to week 28 shall
      be explored and generate initial data on the primary outcome. We hypothesize that SGLT-2
      inhibition and GLP-1 receptor agonism may be a rational combination therapy that addresses a
      broad range of pathophysiological defects associated with T2DM in obesity and may reduce
      HbA1c levels in patients with severe insulin resistance. In a third treatment arm, patients
      will be treated with Exenatide monotherapy added to high-dose intensive Insulin therapy to
      study additive effects of Dapagliflozin and Exenatide.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline (week 0) to week 28</measure>
    <time_frame>28 weeks</time_frame>
    <description>To compare the absolute change from baseline in HbA1c at week 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline (week 0) to week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>To compare the absolute change in HbA1c from baseline at week 0 to week 14 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body weight from baseline (week 0) to week 14 and 28</measure>
    <time_frame>28 weeks</time_frame>
    <description>To compare the change in total body weight from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI from baseline (week 0) to week 14 and 28</measure>
    <time_frame>28 weeks</time_frame>
    <description>To compare the change in BMI from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG from baseline (week 0) to week 14 and 28</measure>
    <time_frame>28 weeks</time_frame>
    <description>To compare the change in fasting plasma glucose (FPG) from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TDID from baseline (week 0) to week 14 and 28</measure>
    <time_frame>28 weeks</time_frame>
    <description>To compare the change in total daily insulin dose (TDID) from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline</measure>
    <time_frame>28 weeks</time_frame>
    <description>To compare the number of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline at week 0 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin plus Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin 10 mg tablet once daily</description>
    <arm_group_label>Dapagliflozin plus Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide 2 mg [Bydureon]</intervention_name>
    <description>Exenatide 2 mg injection once weekly</description>
    <arm_group_label>Dapagliflozin plus Exenatide</arm_group_label>
    <arm_group_label>Placebo plus Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo oral tablet once daily</description>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
    <arm_group_label>Placebo plus Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <description>Placebo injection once weekly</description>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>daily Insulin injections</description>
    <arm_group_label>Dapagliflozin plus Exenatide</arm_group_label>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
    <arm_group_label>Placebo plus Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, if taken before</intervention_name>
    <description>If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.</description>
    <arm_group_label>Dapagliflozin plus Exenatide</arm_group_label>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
    <arm_group_label>Placebo plus Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For inclusion in the study patients should fulfill the following key criteria:

          1. Informed Consent can be obtained prior to any study procedures.

          2. Patient is able to read, understand and sign the Informed Consent.

          3. HbA1c ≥ 8.0% and ≤ 11.0% based on laboratory results

          4. Currently treated with a stable TDID ≥ 80 U at least 3 months prior to enrolment

          5. Patients who are receiving metformin must be on a stable total daily dose ≥ 1500 mg or
             the maximum tolerated dose of metformin within 3 months prior to enrolment

          6. BMI of ≥ 30 kg/m2 at enrolment

          7. Male or female and ≥18 and ≤75 years old at time of informed consent

          8. For female patients:

               -  Not breastfeeding.

               -  Negative pregnancy test result (human chorionic gonadotropin, beta subunit
                  [βhCG]) at Visit 0 (Screening) and Visit 1 (randomization) -not applicable to
                  hysterectomized and post-menopausal females.

               -  If of childbearing potential (including perimenopausal women who have had a
                  menstrual period within 1 year), must practice and be willing to continue to
                  practice appropriate birth control (defined as a method which results in a low
                  failure rate, ie, less than 1% per year, when used consistently and correctly,
                  such as implants, injectables, hormonal contraceptives [pills, vaginal rings, or
                  patches], some intrauterine contraceptive devices [levonorgestrel-releasing or
                  copper-T], tubal ligation or occlusion, or a vasectomized partner) during the
                  entire duration of the study. As applicable, all methods must be in effect prior
                  to receiving the first dose of study medication.

               -  Must practice appropriate birth control as stated above for 10 weeks after the
                  last dose of study medication.

          9. Patients who are receiving the following medications must be on a stable treatment
             regimen for a minimum of 2 months prior to Visit 0 (Screening):

               -  Antihypertensive agents

               -  Thyroid replacement therapy

               -  Antidepressant agents

        Exclusion Criteria:

          1. Diagnosis of Type 1 Diabetes

          2. History of diabetic ketoacidosis, hyperosmolar coma or corticosteroid-induced Type 2
             diabetes

          3. Patients with significant thyroid disease

          4. Patients with history of acute or chronic pancreatitis

          5. Clinically significant cardiovascular disease or procedure within 3 months prior to
             enrolment or expected to require coronary revascularization procedure

          6. Presence of history of severe congestive heart failure (NYHA III and IV)

          7. Creatinin-Clearance of &lt; 60 ml/min based on local laboratory results

          8. Concomitant medication with loop diuretics

          9. Patients who, as judged by the investigator, may be at risk for dehydration or volume
             depletion that may affect the patient's safety (including e.g. patients with a history
             of Diabetes insipidus)

         10. Pregnant women

         11. Administration of any other antidiabetic therapy, other than insulin (see inclusion
             criterion no.4 and 5) and metformin with a stable total daily dose ≥ 1500 mg or the
             maximum tolerated dose of metformin within 3 months prior to enrolment

         12. History of, or currently have, acute or chronic pancreatitis, or have triglyceride
             concentrations ≥ 700 mg/dL (≥ 7.98 mmol/L) at Visit 0 (Screening).

         13. History or presence of inflammatory bowel disease or other severe GI diseases,
             particularly those which may impact gastric emptying, such as gastroparesis or pyloric
             stenosis.

         14. History of gastric bypass surgery or gastric banding surgery, or either procedure is
             planned during the time period of the study. Current use of gastric balloons is also
             excluded.

         15. Significant hepatic disease, including, but not limited to, acute hepatitis, chronic
             active hepatitis, or severe hepatic insufficiency, including patients with alanine
             aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;3x upper limit of
             normal (ULN) and/or total bilirubin (TB) &gt;2 mg/dL (&gt;34.2 μmol/L) (patients with TB &gt;2
             mg/dL [&gt;34.2 μmol/L] and documented Gilbert's syndrome will be allowed to
             participate).

         16. Known history of hepatotoxicity with any medication

         17. Known history of severe hepatobiliary disease.

         18. Positive serological test for hepatitis B or hepatitis C.

         19. Known or suspected human immunodeficiency virus (HIV) infection.

         20. History of organ transplantation.

         21. Presence or history of medullary thyroid carcinoma or multiple endocrine neoplasia
             type 2 (MEN 2) OR a family history of medullary thyroid carcinoma or MEN 2.

         22. Malignancy (with the exception of basal and squamous cell carcinoma of the skin)
             within 5 years of Visit 0 (Screening).

         23. Hemoglobinopathy, hemolytic anemia, or chronic anemia (haemoglobin concentration &lt;11.5
             g/dL [115 g/L] for males, &lt;10.5 g/dL [105 g/L] for females) or any other condition
             known to interfere with the HbA1c methodology.

         24. Patients with abnormal test results of hematocrit (hematocrit &gt; 50% for men;
             hematocrit &gt; 47% for women)

         25. Has donated blood or had a significant blood loss within 2 months of first dose of
             study medication or is planning to donate blood during the study.

         26. Has donated plasma within 7 days prior to first dose of study medication.

         27. Any exposure to Exenatide (including BYETTA®, BYDUREON, or exenatide suspension).

         28. Any exposure to Dapagliflozin or any SGLT-2 inhibitor.

         29. Has been treated, is currently being treated, or is expected to require or undergo
             treatment with any of the following treatment excluded medications:

               -  Any DPP-4 inhibitor within 3 months prior to Visit 0 (Screening).

               -  Any GLP-1 analog within 1 year prior to Visit 0 (Screening).

               -  Systemic corticosteroids within 3 months prior to Visit 0 (Screening) by oral,
                  intravenous, intra-articular, or intramuscular route; or potent, inhaled, or
                  intrapulmonary (including ADVAIR) steroids known to have a high rate of systemic
                  absorption. For examples of excluded steroids, refer to Section 7.7.

               -  Prescription or over-the-counter weight loss medications within 3 months prior to
                  Visit 0 (Screening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Aberle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Lautenbach, MD</last_name>
    <phone>+4915222816188</phone>
    <email>a.lautenbach@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilko TD Wittmann</last_name>
    <phone>+4915222817999</phone>
    <email>h.wittmann@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabeteszentrum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>23758</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schaum, MD</last_name>
      <phone>+494361513622</phone>
      <email>info@diabeteszentrum-oldenburg.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Schaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lautenbach, MD</last_name>
      <phone>+4915222816188</phone>
      <email>a.lautenbach@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Hilko TD Wittmann</last_name>
      <email>h.wittmann@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjoern Paschen, MD</last_name>
      <phone>+4940557753300</phone>
      <email>info@diabetologie-harburg.de</email>
    </contact>
    <investigator>
      <last_name>Bjoern Paschen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Innere Medizin und Diabetologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22607</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Dahl, MD</last_name>
      <phone>+4940896295</phone>
    </contact>
    <investigator>
      <last_name>Dominik Dahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015 Jul 9;4:212283. doi: 10.7573/dic.212283. eCollection 2015. Review.</citation>
    <PMID>26213556</PMID>
  </reference>
  <reference>
    <citation>Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.</citation>
    <PMID>22431673</PMID>
  </reference>
  <reference>
    <citation>Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, Dietz W. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012 Jun;42(6):563-70. doi: 10.1016/j.amepre.2011.10.026.</citation>
    <PMID>22608371</PMID>
  </reference>
  <reference>
    <citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. Erratum in: Diabetes Care. 2013 Feb;36(2):490.</citation>
    <PMID>22517736</PMID>
  </reference>
  <reference>
    <citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0. Epub 2012 Apr 20. Erratum in: Diabetologia. 2013 Mar;56(3):680.</citation>
    <PMID>22526604</PMID>
  </reference>
  <reference>
    <citation>Tatarkiewicz K, Polizzi C, Villescaz C, D'Souza LJ, Wang Y, Janssen S, Parkes DG. Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. Diabetes Obes Metab. 2014 Apr;16(4):376-80. doi: 10.1111/dom.12237. Epub 2013 Dec 9.</citation>
    <PMID>24251534</PMID>
  </reference>
  <reference>
    <citation>Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008 Jan;31(1):173-5. doi: 10.2337/dc08-9016.</citation>
    <PMID>18165348</PMID>
  </reference>
  <reference>
    <citation>Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. Indian J Endocrinol Metab. 2014 Mar;18(2):166-74. doi: 10.4103/2230-8210.129106. Review.</citation>
    <PMID>24741511</PMID>
  </reference>
  <reference>
    <citation>Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu. 2007:13-20.</citation>
    <PMID>18613325</PMID>
  </reference>
  <reference>
    <citation>Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 May;96(5):1301-10. doi: 10.1210/jc.2010-2081. Epub 2011 Feb 9.</citation>
    <PMID>21307137</PMID>
  </reference>
  <reference>
    <citation>Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010 Jun 26;375(9733):2234-43. doi: 10.1016/S0140-6736(10)60406-0.</citation>
    <PMID>20609969</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Jain S. Prevalence of Obesity among Type-2 Diabetics. J Hum Ecol 2009;25:31-5.</citation>
  </reference>
  <reference>
    <citation>Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care. 2002 Feb;25(2):358-63.</citation>
    <PMID>11815510</PMID>
  </reference>
  <reference>
    <citation>2012. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus n.d. ema.europa.eu.</citation>
  </reference>
  <reference>
    <citation>Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf. 2014 Dec;5(6):242-54. doi: 10.1177/2042098614551938. Review.</citation>
    <PMID>25436106</PMID>
  </reference>
  <reference>
    <citation>EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes 2016. www.ema.europe.eu.</citation>
  </reference>
  <reference>
    <citation>Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Erratum in: Lancet Diabetes Endocrinol. 2017 Dec;5(12 ):e8.</citation>
    <PMID>27651331</PMID>
  </reference>
  <reference>
    <citation>FDA approves Farxiga to treat type 2 diabetes. 2014 n.d. fda.gov.</citation>
  </reference>
  <reference>
    <citation>FDA Approves Bydureon Pen. 2014 n.d. drugs.com.</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Exenatide</keyword>
  <keyword>high-dose insulin therapy</keyword>
  <keyword>SGLT-2 inhibitor</keyword>
  <keyword>GLP-1 receptor agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

